ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026
The supporting role of Visual Evoked Potentials for the diagnosis of Optic Neuritis within the 2022 ICON criteria.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisual evoked potentials (VEPs) are commonly used in the assessment of optic neuritis (ON) but were not included in the International Consortium for ON (ICON) 2022 diagnostic criteria as supporting tests.
objectivesWe aimed to assess VEPs diagnostic performances and their addition to the ICON criteria in a large consecutive cohort of patients with suspected ON.
methodsWe screened 207 patients with suspected ON and included 71 who performed MRI, OCT, and VEPs within 30 days from symptoms onset. We calculated diagnostic performances for each test and for the ICON 2022 criteria with and without the addition of VEPs.
resultsVEPs had high overall accuracy (88.7%; 95% confidence interval [CI]: 79.0-95.0) and area under the curve in the ROC analysis (0.89, CI: 0.82-0.97]). The addition of VEPs to the ICON 2022 criteria led to an improvement in sensitivity (100.0%, CI: 92.5-100.0), PPV (88.7%, CI: 79.6-94.0) and NPV (100%, CI: 78.2-100.0), maintaining the same specificity (75.0%, CI: 53.2-90.2), improving diagnostic accuracy to 91.5% (CI: 82.5-96.8).
conclusionsVEPs are reliable for the assessment of suspected ON, and they could be considered as a further paraclinical test in the ICON criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.